BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS

The present invention discloses compounds according to Formula (I) wherein Cy, R1, L1 R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula (I), able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for t...

Full description

Saved in:
Bibliographic Details
Main Authors MAMMOLITI, OSCAR, ORSULIC, MISLAV, MENET, CHRISTEL JEANNE MARIE, BLANC, JAVIER, ROSCIC, MAJA
Format Patent
LanguageEnglish
French
Published 30.07.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention discloses compounds according to Formula (I) wherein Cy, R1, L1 R3, R4, R5, La, and Ra are as defined herein. Novel benzimidazoles according to Formula (I), able to inhibit JAK are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or hypersecretion of interferons. La présente invention concerne des composés selon la formule (I), dans laquelle Cy, R1, L1, R3, R4, R5, La, et Ra sont tels que définis dans la description. Ces nouveaux benzimidazoles de formule (I), qui permettent d'inhiber JAK, peuvent être préparés sous la forme d'une composition pharmaceutique et peuvent être utilisés chez les mammifères, y compris chez l'homme, pour prévenir et traiter divers états pathologiques, dont, entre autres, des maladies allergiques ou des maladies inflammatoires, des maladies auto-immunes, des maladies prolifératives, le rejet de greffe, des maladies impliquant une déficience de renouvellement du cartilage, des malformations congénitales du cartilage, et/ou des maladies associées à une hypersécrétion d'IL6 ou à une hypersécrétion des interférons.
Bibliography:Application Number: CA20152941474